Compare
Arvinas, Inc. vs Ligand Pharmaceuticals Inc vs Vireo Growth Inc. vs Schrodinger, Inc.
| Latest fiscal year | Arvinas, Inc. ARVN | Ligand Pharmaceuticals Inc LGND | Vireo Growth Inc. VREOF | Schrodinger, Inc. SDGR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $262.60M | $268.09M | $268.77M | $255.87M |
| Revenue growth (YoY) | -0.3% | +60.4% | +170.4% | +23.3% |
| Gross margin | n/a | n/a | 47.3% | 55.7% |
| Operating margin | -45.1% | 15.3% | -0.4% | -65.2% |
| Net margin | -30.8% | 46.4% | -25.3% | -40.4% |
| Net income | -$80.80M | $124.45M | -$68.11M | -$103.27M |
| EPS (Diluted) | -$1.14 | $6.13 | -$0.09 | -$1.41 |
| Operating cash flow | -$273.80M | $49.36M | $3.71M | $13.90M |
| Free cash flow | -$275.70M | $48.91M | -$24.61M | $12.46M |
| Cash & equivalents | $142.90M | $174.93M | n/a | $230.52M |
| Total assets | $717.90M | $1.56B | $817.15M | $726.16M |
| Total liabilities | $284.00M | $543.42M | $509.73M | $362.11M |
| Shareholders' equity | $433.90M | $1.02B | $307.42M | $364.05M |
| Return on year-end equity | -18.6% | 12.2% | -22.2% | -28.4% |
| Shares outstanding | 63.50M | 19.77M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Arvinas, Inc. | Ligand Pharmaceuticals Inc | Vireo Growth Inc. | Schrodinger, Inc. |
|---|---|---|---|---|
| Latest | $262.60M Ended 2025-12-31 | $268.09M Ended 2025-12-31 | $268.77M Ended 2025-12-31 | $255.87M Ended 2025-12-31 |
| 1 year earlier | $263.40M Ended 2024-12-31 | $167.13M Ended 2024-12-31 | $99.38M Ended 2024-12-31 | $207.54M Ended 2024-12-31 |
| 2 years earlier | $78.50M Ended 2023-12-31 | $131.31M Ended 2023-12-31 | $88.13M Ended 2023-12-31 | $216.67M Ended 2023-12-31 |
| 3 years earlier | $131.40M Ended 2022-12-31 | $196.25M Ended 2022-12-31 | $74.63M Ended 2022-12-31 | $180.96M Ended 2022-12-31 |
| 4 years earlier | $53.60M Ended 2021-12-31 | $241.54M Ended 2021-12-31 | $54.45M Ended 2021-12-31 | $137.93M Ended 2021-12-31 |